US Material Events SEC 8-K Filings — August 06, 2026

06-08-2026

On August 6, 2026, Quanta Services issued $2.0 billion aggregate principal amount of senior notes across three tranches: $500M of 4.850% notes due 2029, $750M of 5.300% notes due 2033, and $750M of 5.550% notes due 2036. The notes are senior unsecured obligations, not guaranteed by subsidiaries, and were sold via an underwriting agreement led by BofA Securities, Wells Fargo, J.P. Morgan, PNC Capital Markets, and Truist Securities. The proceeds will be used for general corporate purposes, and the issuance increases the company's debt load while extending its maturity profile.

• · The notes are senior unsecured obligations and rank equally with existing and future senior unsecured indebtedness.
• · The notes are effectively junior to secured indebtedness and structurally subordinated to all subsidiary liabilities.
• · Interest on all notes is payable semi-annually in arrears on February 9 and August 9, commencing February 9, 2027.
• · The 2029 notes are redeemable at par after July 9, 2029; the 2033 notes after June 9, 2033; the 2036 notes after May 9, 2036.
• · Upon a Change of Control Triggering Event, holders may require the company to repurchase notes at 101% of principal plus accrued interest.
• · The indenture includes covenants limiting liens, sale-leaseback transactions, and asset sales/mergers.

06-08-2026

The filing announces the August 6, 2026 departure of a named officer (not CEO/CFO) at Arrow Electronics, Inc. The filing triggers Items 5.02, 2.02, 7.01, and 9.01, but the officer's name, role, reason for departure, and all compensation/severance terms are NOT_DISCLOSED in the provided text. The document also references Item 2.02, implying financial results were released, but no revenue, margin, or EPS figures are provided. There is no positive performance data to report, and the only explicit change is an undisclosed departure.

• · Filing size is 1MB, suggesting exhibits are attached but not parsed in this analysis.
• · The filing references Items 2.02, 5.02, 7.01, and 9.01; Item 5.02 is the primary operational change.
• · No indication of whether the departure is voluntary or involuntary, or whether a successor has been appointed.
• · No mention of any financial results, guidance, or capital allocation decisions.

06-08-2026

UNIVERSAL ELECTRONICS INC filed an 8-K on August 6, 2026, reporting results of operations (Item 2.02), a departure/appointment of officers (Item 5.02), and other events (Item 8.01). The filing indicates a leadership change, but specific details on the position affected, reason for departure, and financial metrics are not disclosed in the provided summary. The filing size (460 KB) suggests comprehensive disclosures, but without the full text, the nature of the officer change (resignation vs. appointment) and its financial impact cannot be determined.

• · Filing date: August 6, 2026
• · AccNo: 0000101984-26-000109
• · Filing size: 460 KB
• · Items reported: 2.02 (Results of Operations), 5.02 (Officer Changes), 8.01 (Other Events), 9.01 (Financial Statements and Exhibits)

06-08-2026

Eos Energy Enterprises, Inc. filed an 8-K on August 6, 2026, reporting Items 1.01 (Entry into a Material Definitive Agreement) and 3.02 (Unregistered Sales of Equity Securities). The filing indicates the company entered into a material definitive agreement and conducted an unregistered sale of equity securities, but specific details on the counterparty, dollar value, share count, and strategic rationale are NOT_DISCLOSED. While the filing suggests capital raising activity, the lack of quantitative data prevents a full assessment of the financial impact or market reaction.

• · The filing is a multi-item 8-K covering Items 1.01 and 3.02.
• · No financial statements or exhibits were provided beyond the 8-K form itself (Item 9.01 is listed but no details are disclosed).
• · The unregistered sale of equity securities suggests a private placement or similar transaction, but no pricing, discount, or investor identity is disclosed.
• · No forward-looking statements, guidance, or risk factor changes are included in the filing.

06-08-2026

PubMatic filed an 8-K on August 6, 2026, disclosing results of operations (Item 2.02) and a departure/appointment of officers (Item 5.02). The filing confirms a leadership change, but specific financial results, officer names, and reasons for departure are NOT_DISCLOSED in the provided summary. The filing is timely and compliant with SEC requirements, but without detailed data, the materiality and direction of the change remain uncertain.

• · Filing date: August 6, 2026
• · AccNo: 0001422930-26-000029
• · File size: 392 KB
• · Items disclosed: 2.02 (Results of Operations), 5.02 (Officer Change), 9.01 (Exhibits)

06-08-2026

The filing reports an officer change at American Outdoor Brands, Inc., but no specific details about the position, appointment, resignation, or reason for the change are disclosed. The filing references Items 5.02, 7.01, and 9.01, indicating a departure or appointment of officers, Regulation FD disclosure, and exhibits, but no quantitative data or financial metrics are provided. The absence of specific information limits the ability to assess governance implications or market impact.

• · The filing references Items 5.02, 7.01, and 9.01 of SEC Form 8-K, indicating a leadership change and Regulation FD disclosure.
• · No specific names, titles, or reasons for the officer change are provided in the filing summary.
• · The filing size is 277 KB, suggesting detailed exhibits may be attached, but no financial metrics or quantitative data are extracted.

06-08-2026

Health Catalyst, Inc. filed an 8-K on August 6, 2026, reporting the termination of a material definitive agreement (Item 1.02) and the completion of an acquisition or disposition of assets (Item 2.01). The filing also includes results of operations and financial condition (Item 2.02) and Regulation FD disclosure (Item 7.01). However, the filing does not disclose the counterparty, deal value, or specific financial metrics, limiting the ability to assess the transaction's materiality or strategic impact.

• · Filing includes Item 1.02 (Termination of Material Definitive Agreement) and Item 2.01 (Completion of Acquisition or Disposition of Assets), but no specific counterparty, deal value, or asset details are disclosed.
• · Item 2.02 (Results of Operations and Financial Condition) is referenced but no financial metrics (revenue, EPS, etc.) are provided in the filing summary.
• · Item 7.01 (Regulation FD Disclosure) is included, suggesting a concurrent public disclosure, but content is not specified.
• · No scheduled events (e.g., earnings calls, shareholder meetings) are mentioned in the filing.

06-08-2026

CDT Equity Inc. filed an 8-K on August 6, 2026, reporting multiple material events: entry into a material definitive agreement (Item 1.01), creation of a direct financial obligation (Item 2.03), and unregistered sales of equity securities (Item 3.02). The filing is multi-item and mandatory, but no specific dollar values, share counts, or transaction details are disclosed. The filing lacks quantitative data, making it impossible to assess financial impact or market reaction.

06-08-2026

Pulse Biosciences, Inc. filed an 8-K on August 6, 2026, reporting under Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits). The filing indicates a material agreement was entered into, but specific financial terms, the nature of the agreement, and the counterparty were not disclosed in the provided summary. The filing is timely and mandatory, but the lack of detail limits the ability to assess strategic or financial impact.

• · Filing date: 2026-08-06
• · Accession Number: 0001437749-26-026351
• · File size: 429 KB
• · Sector: not specified

06-08-2026

ProPhase Labs, Inc. filed an 8-K on August 6, 2026, reporting entry into a material definitive agreement (Item 1.01) and creation of a direct financial obligation (Item 2.03). The filing does not disclose specific financial terms, transaction value, or counterparty details. No quantitative data on revenue, earnings, or guidance changes are provided, limiting the ability to assess materiality or market impact.

• · Filing includes Item 9.01 (Financial Statements and Exhibits) but no exhibits are specified in the summary.
• · Sector is not specified in the filing metadata.
• · No insider trading activity or beneficial ownership changes are mentioned.

06-08-2026

UWM Holdings Corp filed a multi-item 8-K on August 6, 2026, covering entry into a material definitive agreement (Item 1.01), results of operations (Item 2.02), unregistered sales of equity securities (Item 3.02), director/officer changes (Item 5.02), amendments to articles of incorporation (Item 5.03), and other events (Item 8.01). The filing indicates significant corporate activity including a new agreement, financial results, equity issuance, leadership changes, and governance updates. However, specific financial metrics, transaction values, and detailed terms are not disclosed in the summary, limiting quantitative analysis.

• · Multi-item 8-K filed on August 6, 2026, covering 7 distinct items (1.01, 2.02, 3.02, 5.02, 5.03, 8.01, 9.01).
• · Item 1.01 indicates a material definitive agreement was entered into, but no counterparty or terms are disclosed.
• · Item 2.02 reports results of operations and financial condition, suggesting the filing may coincide with an earnings release.
• · Item 3.02 involves unregistered sales of equity securities, which could indicate a private placement or PIPE transaction.
• · Item 5.02 signals changes in board or officer composition, including potential departures or appointments.
• · Item 5.03 indicates amendments to the company's charter or bylaws, possibly related to governance or capital structure changes.
• · Item 8.01 covers other events not captured by other items, adding to the complexity of the filing.
• · No specific financial metrics, transaction values, or executive names are provided in the summary.
• · The filing size (4 MB) suggests detailed exhibits are attached, but their content is not summarized.

06-08-2026

Ensysce Biosciences acquired Cy Biopharma in a stock-for-stock merger, gaining a clinical-stage neuroplastogenic therapy (CY-200) for Complex Regional Pain Syndrome (CRPS) with FDA Orphan Drug Designation. Concurrently, the company secured up to $77 million in total financing: $21.5 million from an initial private placement (led by Ally Bridge Group, with Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners), $17.1 million in cash from Cy Biopharma's pre-acquisition convertible note, and up to $38.6 million upon a clinical milestone. Pro forma cash is expected to fund CY-200 through Phase 2 proof-of-concept data and into registrational development, while Ensysce continues its PF614-MPAR program. However, the transaction requires stockholder approval for the Series C Preferred Stock conversion, and the company faces risks including potential Nasdaq delisting and failure to achieve the milestone for the second tranche.

• · The acquisition is structured as a stock-for-stock merger with a fixed exchange ratio for 282,122 shares of Series C Preferred Stock (282,122,000 on as-converted basis).
• · Series C Preferred Stock conversion ratio is 1:1,000 to common stock, subject to stockholder approval and beneficial ownership limitations.
• · The private placement price is $321.79 per share ($0.32179 per share on as-converted basis) for the initial tranche and $402.24 per share ($0.40224 per share on as-converted basis) for the milestone tranche.
• · The company resolved existing contractual matters with a third party by converting outstanding Series B Preferred Stock and warrants into common and Series C Preferred Stock.
• · The initial close of the private placement is expected on August 7, 2026.
• · The milestone closing is contingent on achievement of a clinical trial milestone.
• · Risks include possible Nasdaq delisting, failure to obtain stockholder approval for conversion, and failure to achieve the clinical milestone for the second tranche.
• · The combined fully diluted equity value is approximately $101.4 million (excluding transaction fees).

06-08-2026

Honda Auto Receivables 2026-3 Owner Trust filed an 8-K on August 6, 2026, reporting the entry into an Underwriting Agreement on August 4, 2026, for the issuance of $2,105,270,000 in asset-backed notes across five classes (Class A-1 through A-4) with coupons ranging from 3.964% to 4.62% (plus a SOFR-linked tranche). The transaction involves the securitization of Honda and Acura auto loan receivables, with closing expected on August 12, 2026. American Honda Finance Corporation will retain at least 5% of each note class, and multiple ancillary agreements (Receivables Purchase, Sale and Servicing, Administration, Trust, and Asset Representations Review) will be executed at closing.

• · The Underwriting Agreement was entered into on August 4, 2026, with BofA, BNP Paribas, Citigroup, and US Bancorp as representatives of the underwriters.
• · The Issuer was established under a Trust Agreement dated July 8, 2026, to be amended and restated as of the Closing Date.
• · AHFC will retain at least 5% (by initial principal amount) of each class of Notes.
• · The Receivables consist of retail installment sale contracts or installment loan contracts for new or used Honda or Acura automobiles.
• · Clayton Fixed Income Services LLC will serve as asset representations reviewer.
• · The CEO of the registrant made the certifications required by Paragraph I.B.1(a) of Form SF-3, filed as Exhibit 36.1.

06-08-2026

ProFrac Holding Corp. reported Q2 2026 revenue of $498M (up 10.7% QoQ from $450M) and a net loss of $75M (improved from a net loss of $81M in Q1). Adjusted EBITDA rose to $69M (14% of revenue) from $54M (12% of revenue), and free cash flow improved to negative $8M from negative $25M. However, the Proppant Production segment faces incremental competitive pricing pressure, and the company expects only flat results in that segment for Q3. Additionally, CEO Ladd Wilks will resign effective August 7, 2026, and Executive Chairman Matt Wilks will assume the combined role of CEO and Executive Chairman.

• · Stimulation Services segment generated $430M revenue and $39M Adjusted EBITDA (9% margin) in Q2 2026.
• · Proppant Production segment generated $121M revenue and $6M Adjusted EBITDA (5% margin) in Q2 2026; 87% of revenue was intercompany.
• · Manufacturing segment generated $48M revenue and $6M Adjusted EBITDA (13% margin) in Q2 2026; 82% of revenue was intercompany.
• · Flotek segment generated $102M revenue and $19M Adjusted EBITDA (19% margin) in Q2 2026; 58% of revenue was intercompany.
• · Other Business Activities generated $3.6M revenue and $0.4M Adjusted EBITDA (11% margin) in Q2 2026.
• · Full year 2026 capital expenditure guidance: $155M-$185M including Flotek; $145M-$175M excluding Flotek.
• · Total principal debt outstanding as of June 30, 2026: $1.10B; net debt: $1.08B.
• · Total cash and cash equivalents as of June 30, 2026: $19M, of which $5M was related to Flotek and not accessible by the Company.
• · Liquidity as of June 30, 2026: $72M ($14M cash excluding Flotek + $58M ABL availability).
• · On July 1, 2026, the Company refinanced its $275M ABL facility with a new $300M ABL facility; as of July 1, 2026, eligible borrowing base was $243M, with $173M drawn and $71M remaining availability.
• · Proppant Production segment faces incremental competitive pricing pressure, particularly in West Texas.
• · ProFrac expects Q3 2026 Stimulation Services results to improve QoQ driven by pricing increases and steady utilization; Proppant Production expected to be approximately flat.
• · RFP season conversations are unfolding earlier than typical, indicating potential equipment tightness into 2027.

06-08-2026

Yum China Holdings, Inc. entered into a senior unsecured delayed draw term loan facility (bridge credit agreement) dated July 31, 2026, with HSBC Bank USA as administrative agent and HSBC Securities (USA) Inc. and Citigroup Global Markets Asia Limited as joint lead arrangers. The facility is intended to finance the acquisition of the Pizza Hut Target (the 'Pizza Hut Acquisition'), with an availability period ending November 16, 2026. The agreement includes financial covenants and a CNH HIBOR-based interest rate margin that increases over time, reflecting a temporary financing structure.

• · The facility is a senior unsecured delayed draw term loan facility.
• · The availability period ends on November 16, 2026, or upon closing of the Pizza Hut Acquisition, whichever is earlier.
• · The agreement includes financial covenants (Section 10.6) and a post-closing covenant (Section 10.16).
• · The loan is denominated in CNH (offshore Chinese Yuan).
• · The agreement includes provisions for defaulting lenders, increased costs, and market disruption.
• · The facility is intended to finance the acquisition of the Pizza Hut Target, which is a significant strategic move for Yum China.

06-08-2026

Karman Holdings Inc. entered into a Fifth Amendment to its Credit Agreement on August 3, 2026, obtaining $763,961,000 in new July 2026 Refinancing Term Loans to fully refinance its existing term loans. The amendment also reduces the Applicable Rate on both term loans and revolving credit loans, lowering borrowing costs. The refinancing was executed through a cashless exchange with existing term lenders and involves joint lead arrangers including Citibank, Royal Bank of Canada, and others.

• · The Fifth Amendment was entered into on August 3, 2026, and filed on August 6, 2026.
• · The refinancing was conducted under Section 2.18 of the Credit Agreement as a Specified Refinancing Term Loan.
• · Existing term lenders could exchange their existing term loans for new term loans of equal principal amount via a cashless exchange.
• · The new term loans initially bear interest as SOFR Loans with an initial Interest Period ending September 30, 2026.
• · The Applicable Rate for revolving credit loans was also reduced, with rates ranging from 1.50% to 2.00% for SOFR Loans depending on leverage ratio.
• · Joint lead arrangers and bookrunners for the amendment include Citibank, Royal Bank of Canada, Keybanc Capital Markets, Texas Capital Securities, and The Huntington National Bank.

06-08-2026

First Advantage reported record Q2 2026 revenues of $448.8 million, up 14.9% year-over-year, and adjusted EBITDA of $128.5 million, with net income of $16.9 million (3.8% margin) improving sharply from $0.3 million in the prior-year quarter. The company raised its full-year 2026 guidance across all key metrics, including revenue to $1.67B-$1.71B and adjusted EPS to $1.23-$1.29. However, adjusted EBITDA margin declined slightly to 28.6% from 29.2% in Q2 2025, and cash flow from operations of $73.6 million faced comparison with seasonal patterns.

• · Full year 2026 revenue guidance raised to $1.67B-$1.71B from prior $1.625B-$1.700B.
• · Full year 2026 adjusted EBITDA guidance raised to $472M-$486M from prior $460M-$485M.
• · Full year 2026 adjusted diluted EPS guidance raised to $1.23-$1.29 from prior $1.15-$1.25.
• · Diluted net income per share was $0.10 in Q2 2026 versus $0.00 in Q2 2025.
• · Voluntary debt prepayments of $45M on August 4 and $25M on May 6 reflecting deleveraging focus.
• · About 1.9% of total shares outstanding repurchased through July 31, 2026.

06-08-2026

Exyn Technologies adopted a Non-Employee Director Compensation Program and approved new equity grants for its four non-employee directors and CEO. The CEO's base salary was increased to $482,000 with a target annual bonus of 75% of salary ($362,000). The changes reflect the company's transition to a public company following its IPO, with no negative financial metrics reported.

• · The Director Compensation Program is effective as of August 3, 2026.
• · Non-employee directors may elect to receive cash retainers in the form of stock options or restricted stock units.
• · Annual equity grants cliff vest on the earlier of the first anniversary or the day before the next annual meeting.
• · Initial equity grants for new directors vest ratably over three years.
• · CEO stock option vests in equal monthly installments over four years with a one-year cliff.
• · No per-meeting fees are paid to non-employee directors.

06-08-2026

Saratoga Investment Corp. filed an 8-K on August 6, 2026, reporting a change in directors or certain officers (Item 5.02) effective August 5, 2026. The filing contains no financial results, no quantitative data, and no period-over-period comparisons. The disclosure is limited to a routine officer/director departure or election with no material financial impact.

• · Filing type: 8-K under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers)
• · Event date: August 5, 2026
• · Company is a Maryland corporation with fiscal year ending February 28
• · Company has multiple classes of notes registered: 6.00% Notes due 2027, 8.00% Notes due 2027, 8.125% Notes due 2027, 8.50% Notes due 2028, and 7.50% Notes due 2031

06-08-2026

Rush Enterprises, Inc. (RUSHA/RUSHB) announced amendments to two credit agreements with Bank of Montreal (BMO) for its Canadian subsidiary, Rush Truck Centres of Canada Limited (RTC-Canada). The amendments extend the expiration dates of both the BMO Revolving Lease and Rental Credit Agreement and the BMO Wholesale Financing and Security Agreement to December 31, 2029. The revolving credit agreement also removed a $20.0 million CAD accordion feature that RTC-Canada determined it does not need.

• · The Second Amendment to the BMO Revolving Lease and Rental Credit Agreement was effective August 4, 2026.
• · The Fifth Amendment to the Amended and Restated BMO Wholesale Financing and Security Agreement was effective August 4, 2026.
• · The original BMO Revolving Lease and Rental Credit Agreement was dated July 15, 2022.
• · The original Amended and Restated BMO Wholesale Financing and Security Agreement was dated July 15, 2022.

06-08-2026

Bausch & Lomb Corp filed an 8-K on August 6, 2026, reporting multiple material events including entry into a definitive agreement (Item 1.01), director/officer changes and compensatory arrangements (Item 5.02), and other events (Item 8.01). The filing does not disclose specific financial terms, transaction values, or performance metrics, limiting quantitative analysis. While the filing indicates significant corporate actions, the lack of disclosed details prevents a directional assessment of financial impact.

• · Filing date: August 6, 2026
• · Filing size: 261 KB
• · AccNo: 0000950103-26-011979
• · Multiple items reported: 1.01, 5.02, 8.01, 9.01
• · No specific financial terms, transaction values, or performance metrics disclosed in the summary

06-08-2026

Sunrise Realty Trust, Inc. (SUNS) announced a definitive merger agreement to acquire Southern Realty Trust Inc. (SRT), consolidating two transitional CRE lenders focused on the Southern U.S. into a single public company. The combined entity would have pro forma total assets of $534 million and total loan commitments of $604 million as of June 30, 2026. The merger is expected to enhance stockholder value through increased margin, broader index inclusion, improved trading liquidity, and access to more efficient leverage, with potential annual G&A savings and a reduction in the incentive fee rate from 20% to 17.5% and the hurdle rate from 8% to 7%.

• · The merger is expected to close in Q4 2026, subject to stockholder approvals and customary closing conditions, with no financing condition.
• · A 30-day go-shop period expires at 12:01 a.m. ET on September 5, 2026.
• · Each SRT share will be converted into 1.45 shares of SUNS common stock plus $0.05 cash per share.
• · SUNS expects to issue approximately 8.4 million shares of common stock as stock consideration.
• · Certain SUNS stockholders (~28%) and SRT stockholders (~32%) have entered into voting agreements to support the transaction.
• · Certain SRT stockholders (~32%) have agreed to 120-day lock-up restrictions post-closing.
• · SRT's external manager will fund a special distribution to SRT stockholders prior to closing and waive any termination fee.
• · The SUNS board will be expanded to include one independent director designated by SRT.
• · The combined company will continue to trade on Nasdaq under the ticker 'SUNS' and be externally managed by SUNS Manager.

06-08-2026

Lithium Americas Corp. (LAC) entered into a securities purchase agreement with Yorkville Advisors for up to $175 million in subordinated convertible debentures to strengthen its liquidity as Thacker Pass approaches peak construction. The financing complements the $2.23 billion DOE loan and strategic investments from GM and Orion. The company targets late 2027 mechanical completion for Phase 1, which is designed to produce 40,000 tonnes per year of battery-grade lithium carbonate.

• · The company has agreed to suspend sales under its at-the-market equity program for 30 days following the initial closing.
• · Proceeds will be used for general corporate purposes including capital expenditures, debt repayment, and working capital.
• · The company is relying on TSX Section 602.1 exemption for eligible interlisted issuers.
• · Thacker Pass hosts the largest known measured lithium resource (Measured and Indicated) in the world.
• · Mechanical completion for Phase 1 is targeted for late 2027.

06-08-2026

Genesco Inc. announced the retirement of Parag D. Desai, Senior Vice President, Chief Strategy and Digital Officer, effective October 31, 2026, after more than a decade of service. The filing highlights his contributions to strategic initiatives and technology transformation, but provides no financial metrics or performance data for the period.

• · Desai joined Genesco in 2014 as SVP, Strategy and Shared Services, and was named SVP, Chief Strategy and Digital Officer in April 2021.
• · His responsibilities will transition to other experienced members of the senior leadership team.
• · Genesco operates more than 1,200 retail stores and branded e-commerce websites.
• · Brands include Journeys, Little Burgundy, Schuh, Johnston & Murphy, and Genesco Brands Group (licensed brands: Wrangler, Dockers, Starter).

06-08-2026

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million upfront ($270M cash + $180M stock) plus up to $350 million in regulatory and sales milestones. The deal adds gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease with no FDA-approved treatments, and expands Tarsus' retina pipeline alongside IRX-101. While the acquisition adds a potential blockbuster opportunity, it carries significant execution risk as top-line Phase 3 data is not expected until the second half of 2029, and the company will incur dilution from the stock component.

• · Tarsus common stock issued to Alkeus stockholders will be priced at $61.38 per share.
• · The acquisition is not contingent on financing; it has been approved by both boards and Alkeus stockholders.
• · Closing expected in 2026, subject to HSR antitrust waiting period and customary conditions.
• · Gildeuretinol has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the FDA.
• · No treatment-related effects on night vision, dark adaptation, or color vision have been reported to date.
• · The primary endpoint of NORTHSTAR is rate of retinal atrophic lesion growth over 24 months; secondary endpoint is change in low light visual acuity.
• · Royalties on gildeuretinol net sales are low single digit tiered descending.
• · Tarsus is also developing TP-04 for ocular rosacea and TP-05 for Lyme disease prevention, both in Phase 2.

06-08-2026

Vistance Networks (NASDAQ: VISN) announced a special cash distribution of $5.00 per share, payable on August 27, 2026, to shareholders of record as of August 17, 2026. The distribution is funded by proceeds from the sale of its Ruckus Networks business to Belden Inc. on July 1, 2026. The ex-dividend date is August 28, 2026, due to the distribution being 25% or greater of the stock's value.

• · Record date: August 17, 2026
• · Payment date: August 27, 2026
• · Ex-dividend date: August 28, 2026 (first business day after payment)
• · Distribution funded by proceeds from sale of Ruckus Networks to Belden Inc. on July 1, 2026

06-08-2026

Vital Farms reported Q2 2026 net revenue of $166.0M, down 10.1% YoY from $184.8M, swinging to a net loss of $31.1M from net income of $16.6M in the prior-year quarter, driven by industry-wide oversupply and price gap pressure. The company grew retail dollar share of the shell egg category by over 200 bps YoY despite category pricing falling more than 35% YoY, and announced new $185M credit facilities while terminating its stock repurchase program. Management reaffirmed FY2026 net revenue guidance of $775M-$800M and Adjusted EBITDA guidance of $0-$10M, expecting a margin recovery in H2 2026.

• · Net revenue from retail channel was $158.0M in Q2 2026 vs $176.1M in Q2 2025.
• · Excess sales to breaker and wholesale channels contributed only $0.1M to net revenue growth, as a large volume increase was almost entirely offset by a price decline.
• · Gross profit decrease of $60.9M YoY was driven by $19.5M from excess breaker sales, $0.8M farmer contract amendment amortization, and $7.8M butter business exit costs.
• · Loss from operations was $40.1M in Q2 2026 vs income from operations of $23.8M in Q2 2025.
• · Stock repurchased early in Q2 2026: 1,129,104 shares at average price of $13.29 per share, for aggregate cost of $15.0M.
• · Stock repurchase program terminated on August 3, 2026, consistent with terms of new lending facilities.
• · New credit facilities: $125M 3-year term loan and $60M 3-year asset-based lending facility, replacing previous revolving credit facility.
• · FY2026 capital expenditures guidance reduced to $70M-$75M, reflecting decision to slow pace of capital spending, particularly at Vital Crossroads and new accelerator farms.
• · Adjusted EBITDA guidance of $0-$10M reflects negative impact in mid-$30M range from costs to manage current oversupply of eggs.
• · Underlying gross margin excluding $28.1M of supply-management and other discrete expenses was meaningfully more favorable.
• · Net cash used in operating activities was $45.9M for 26-week period ended June 28, 2026, compared to net cash provided by $4.5M in prior-year period.
• · Capital expenditures increased 275% YoY to $37.5M in H1 2026 from $10.0M in H1 2025.

06-08-2026

Korro Bio reported Q2 2026 financial results with a net loss of $18.9 million, improved from a $25.8 million loss in Q2 2025. The company ended the quarter with $137.9 million in cash, providing runway into H2 2028. Key pipeline progress includes KRRO-121 (hyperammonemia) on track for first-in-human trial in H2 2026 and nomination of KRRO-111 (AATD) as a development candidate. However, collaboration revenue fell to zero from $1.5 million a year ago due to a pause in the Novo Nordisk agreement, and R&D expenses declined 32% to $13.6 million.

• · KRRO-121 received Orphan Drug Designation from EMA for urea cycle disorders.
• · KRRO-111 demonstrated over 90% editing of SERPINA1 transcript in vivo and approximately 90% repaired functional AAT protein in plasma in a mouse model.
• · KRRO-111 showed reduction of non-inclusion Z-AAT by approximately 95% and reduction in pre-existing aggregates by approximately 62% at day 28.
• · The company expects to nominate a development candidate for a third GalNAc-conjugated program in H2 2026.
• · Cash runway extends into the second half of 2028.
• · The collaboration with Novo Nordisk was paused for 12 months in November 2025, resulting in zero collaboration revenue in Q2 2026.

06-08-2026

HARROW, INC. filed an 8-K on August 6, 2026, reporting Items 1.01, 7.01, and 9.01. The filing indicates entry into a material definitive agreement, but specific terms, financial impact, and strategic details are not disclosed. The filing is timely and includes exhibits, but the lack of quantitative data limits analysis.

• · Filing date: 2026-08-06
• · Accession Number: 0001493152-26-036256
• · File size: 279 KB
• · Items reported: 1.01, 7.01, 9.01

06-08-2026

Arteris, Inc. announced the appointment of Saurabh Sinha as Chief Financial Officer, effective September 8, 2026, succeeding Nick Hawkins who is retiring after seven years with the company. Hawkins will remain as an executive advisor through February 2027 to ensure a smooth transition. Sinha brings over 25 years of financial leadership experience, most recently as CFO of Aeva Technologies.

• · Saurabh Sinha appointed CFO effective September 8, 2026
• · Nick Hawkins retiring after seven years, will serve as executive advisor through February 2027
• · Sinha previously CFO of Aeva Technologies since September 2020
• · Sinha holds a Bachelor of Commerce from University of Delhi and MBA from Wharton School

06-08-2026

Vystar Corporation entered into a joint venture with Capital Realm, Inc. to acquire a 50% interest each in r3alm, Inc., a compliance-focused AI and Web3 financial ecosystem. Vystar issued 8,371 shares of Series B preferred stock (convertible into 8,371,000 common shares, representing 34% ownership) to Capital Realm, with the shares fully vesting upon proof of intellectual property concept. The transaction was exempt under Regulation D.

• · Joint venture formed on August 4, 2026, with agreements dated July 28, 2026.
• · Vystar issued 8,371 Series B preferred shares convertible into 8,371,000 common shares (34% ownership) to Capital Realm.
• · Shares fully vest upon proof of intellectual property concept.
• · Transaction exempt under Regulation D of the Securities Act of 1933.
• · R3alm platform includes 22 planned modules spanning digital capital formation, tokenized assets, governance, trading, treasury, identity, analytics, and AI-powered financial intelligence.
• · Platform aims to help small and micro-cap companies tokenize stocks for 24-hour domestic and international trading.

06-08-2026

Virtuix Holdings Inc. (VTIX) announced a change in its independent registered public accounting firm on August 4, 2026, with EisnerAmper LLP replacing M&K CPAS, PLLC for the fiscal year ending March 31, 2027. The change was approved by the Audit Committee, and there were no disagreements or reportable events between the company and M&K during the past two fiscal years, though M&K's reports included a going concern explanatory paragraph.

• · Change of auditor from M&K CPAS, PLLC to EisnerAmper LLP effective August 4, 2026.
• · M&K's reports for fiscal years ended March 31, 2026 and 2025 included a going concern explanatory paragraph.
• · No disagreements or reportable events occurred between the company and M&K during the past two fiscal years.
• · The company is an emerging growth company and has elected not to use the extended transition period for new accounting standards.

06-08-2026

Mastech Digital reported Q2 2026 total revenues of $41.4M, down 15.6% YoY but up 0.9% sequentially. The Data & AI segment showed strength with 7.2% sequential revenue growth and bookings of $13.5M, while the Talent segment continued to decline 16.2% YoY due to client insourcing. GAAP net loss was $0.1M, compared to GAAP net income of $0.1M in Q2 2025, and non-GAAP net income fell to $1.0M from $1.8M.

• · Data & AI segment bookings surged 50% YoY to $13.5M in Q2 2026 from $9.0M in Q2 2025.
• · Talent segment billable consultants declined 22.3% since Q2 2025, driven by a top ten client insourcing and exit from lower-margin positions.
• · Average bill rate improved to $92.17 in Q2 2026 from $88.36 in Q2 2025, a 4.3% increase.
• · Total liquidity stood at $56.0M as of June 30, 2026, including $35.6M cash and $20.4M undrawn credit facility, with no bank debt.
• · GAAP diluted loss per share was ($0.01) in Q2 2026 vs. diluted EPS of $0.01 in Q2 2025.
• · Non-GAAP diluted EPS fell to $0.08 in Q2 2026 from $0.15 in Q2 2025.
• · Selling, general and administrative expenses decreased to $12.3M in Q2 2026 from $13.8M in Q2 2025.
• · Income from operations was a loss of $0.3M in Q2 2026 vs. income of $27K in Q2 2025.

06-08-2026

The filing is an 8-K by TerrAscend Corp. reporting multiple items including results of operations (Item 2.02), a departure of directors or officers (Item 5.02), and Regulation FD disclosure (Item 7.01). However, the filing text itself is not provided, so no specific officer names, reasons for departure, financial results, or other quantitative data can be extracted. The filing appears to be a standard SEC disclosure, but without the actual content, no material positive or negative metrics can be identified.

06-08-2026

The filing reports the departure of a director, Dr. Michael B. McCallister, who did not stand for re-election at the 2026 Annual Meeting of Shareholders, effective May 7, 2026. His departure is a routine retirement and not due to any disagreement with the company. The board reduced its size from 13 to 12 directors. The filing also includes the approval of the 2026 Equity and Incentive Plan and the 2026 Employee Stock Purchase Plan, which are routine compensatory arrangements. No negative metrics or performance declines are reported.

• · The director's departure was not due to any disagreement with the company on any matter relating to the company's operations, policies, or practices.
• · The board reduced its size from 13 to 12 directors effective May 7, 2026.
• · The 2026 Equity and Incentive Plan authorizes up to 10,000,000 shares of common stock for issuance.
• · The 2026 Employee Stock Purchase Plan authorizes up to 3,000,000 shares of common stock for issuance.
• · The filing includes the company's press release dated August 6, 2026, announcing the director's retirement.

06-08-2026

STAAR Surgical announced the appointment of Warren Foust as President and CEO, effective August 4, 2026, following an extensive global search. Deborah Andrews, who served as Interim Co-CEO, will become EVP and continue as CFO. The company highlighted a strong first half with robust year-over-year growth, increasing profitability, and market share gains, particularly in China, but also noted risks including reliance on international markets and economic conditions.

• · Warren Foust joined STAAR in April 2023 as COO, became President and COO in March 2025, and Interim Co-CEO in February 2026.
• · Deborah Andrews rejoined STAAR in March 2025 as Interim CFO, appointed CFO in June 2025, and Interim Co-CEO in February 2026.
• · The company has sold more than 4 million ICLs in over 85 countries.
• · STAAR has been designing, developing, manufacturing, and marketing ICLs for over 30 years.
• · The company operates facilities in California and Switzerland.

06-08-2026

CreditRiskMonitor.com, Inc. disclosed it will restate financial statements for fiscal years 2024 and 2025 and certain quarterly periods due to previously uncollected and unremitted sales/use and income taxes in state and local jurisdictions. The company expects to record a sales tax liability of approximately $1,767 thousand and an income tax liability of approximately $210 thousand. A material weakness in internal control over financial reporting related to tax nexus requirements has been identified, and a remediation plan is underway.

• · The restatement affects audited financial statements for fiscal years ended December 31, 2025 and 2024, and unaudited quarterly periods ended June 30, 2025, September 30, 2025 and 2024, and March 31, 2026 and 2025.
• · The material weakness relates to internal controls over identification, monitoring, and evaluation of state and local tax nexus requirements.
• · Management's conclusions on internal control over financial reporting will be included in the 2026 Annual Report on Form 10-K.
• · The company is a remote-only entity with no physical headquarters.

06-08-2026

iRhythm Technologies, Inc. filed a Form 8-K on August 6, 2026, reporting multiple material events including a material definitive agreement (Item 1.01), financial results (Item 2.02), and Regulation FD disclosure (Item 7.01). The filing indicates both positive revenue growth and operational improvements, but also highlights ongoing net losses and increased operating expenses, reflecting a mixed financial performance.

• · The filing includes a material definitive agreement (Item 1.01), but specific terms are not disclosed in the summary.
• · Financial results (Item 2.02) show revenue growth but also net losses, indicating ongoing profitability challenges.
• · Regulation FD disclosure (Item 7.01) suggests management provided additional information to select investors or analysts.
• · Exhibits (Item 9.01) include financial statements and other supporting documents.

06-08-2026

Willis Lease Finance Corp. (WLFC) entered into a Purchase and Sale Agreement on August 3, 2026, to acquire three commercial buildings totaling 375,000 square feet in Coconut Creek, Florida for $118.0 million. The properties will support the company's expanding operations, including its corporate headquarters, spare parts business, MRO services, and engine storage. The acquisition is subject to customary closing conditions.

• · The acquired buildings are located in Coconut Creek, Florida.
• · The company intends to use the properties for corporate headquarters, spare parts business, MRO services, and engine storage.
• · Closing is subject to customary closing conditions.

06-08-2026

The filing reports the departure of INNODATA INC's Chief Financial Officer, effective August 6, 2026, with no reason stated. The company also announced the appointment of a new CFO, effective the same date. No financial results or other material operational metrics were disclosed in this filing.

• · The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), but no financial data or exhibits were provided in the summary.
• · No reason for the CFO's departure was stated.
• · The new CFO's background, compensation, and whether the appointment is internal or external are not disclosed.

06-08-2026

Brady Corp filed an 8-K on August 6, 2026, reporting the completion of an acquisition (Item 2.01) and entry into a material definitive agreement (Item 1.01), along with related obligations (Item 2.03) and Regulation FD disclosure (Item 7.01). However, the filing does not disclose the target company, deal value, or financial terms, limiting the ability to assess materiality or strategic impact.

• · The filing includes Item 7.01 (Regulation FD Disclosure), suggesting a concurrent press release or investor presentation was issued.
• · Item 9.01 indicates financial statements and exhibits are attached, but no details are provided in the summary.
• · No target company name, deal value, or financial impact is disclosed in the filing summary.

06-08-2026

Beachbody Company, Inc. (BODi) announced a second amendment to its credit agreement with Tiger Finance, LLC, which streamlines financial covenants, eliminates the billings fixed charge coverage ratio, and adjusts minimum digital subscriptions and Three Month Total Billings targets. The amendment reduces the cash balance threshold required to avoid testing these two covenants by approximately $7 million, and the company must maintain a minimum liquidity of $18 million, stepping down to $16 million by March 2027. The company reported a cash position of $36.6 million as of March 31, 2026, exceeding its $23.6 million debt level by $13.0 million, reflecting a strengthened balance sheet.

• · The amendment eliminates the billings fixed charge coverage ratio covenant.
• · The minimum liquidity level will decrease by approximately $0.2 million monthly beginning March 1, 2027, to $16 million.
• · The company's cash position of $36.6 million on March 31, 2026, exceeded its $23.6 million debt level by $13.0 million.

06-08-2026

The filing is an 8-K regarding an officer change at Hyster-Yale, Inc., but no specific details about the position, person, or reason for the change are disclosed in the provided text. The filing references Item 5.02, which covers director or officer departures, appointments, or compensatory arrangements, but the actual content of the change is not included. Without specific data on the leadership change, the analysis is limited, and no positive or negative metrics are available to report.

• · The filing was made on August 6, 2026, with accession number 0001173514-26-000213.
• · The filing size is 142 KB, but the specific details of the officer change are not provided in the extracted text.

06-08-2026

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) achieved its first development milestone under its Amended and Restated Exclusive License Agreement with Statera Biopharma, triggering a $750,000 milestone payment. The company issued 1,287.8685 shares of Series A Preferred Stock to Statera and Avenue Venture Opportunities Fund as partial consideration for the milestone payment. The company also entered into a Securities Purchase Agreement with Avenue providing registration rights for the underlying common shares.

• · The milestone payment of $750,000 can be paid in either cash or company stock at the company's sole discretion.
• · The company has the option to accelerate any milestone payments for Subsequent Indications in advance of milestone achievements.
• · The Series A Preferred Stock includes a conversion limitation preventing any holder from converting if it would result in beneficial ownership exceeding a specified percentage between 4.9% and 19.9%.
• · The company must file a resale registration statement with the SEC within 60 calendar days following the closing date of the Purchase Agreement.
• · The company's common stock trades on Nasdaq under the symbol VBIO.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

06-08-2026

N2OFF, Inc. (NITO) dismissed KPMG Israel as its independent auditor and appointed Deloitte Israel as its new auditor, effective August 6, 2026. The change was approved by the board and audit committee, with no disagreements or reportable events in the prior two fiscal years. KPMG Israel's audit reports for 2024 and 2025 included a going concern qualification, reflecting the company's recurring losses and net capital deficiency.

• · KPMG Israel's audit reports for fiscal years 2024 and 2025 contained a going concern qualification due to recurring losses and net capital deficiency.
• · No disagreements or reportable events occurred between the company and KPMG Israel during the two most recent fiscal years.
• · The company did not consult Deloitte Israel on any matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K prior to engagement.

06-08-2026

Grace Therapeutics, Inc. announced a $10 million private placement with new and existing investors, issuing 4,761,904 shares at $2.10 per share, expected to close August 6, 2026. The net proceeds, together with existing cash, are expected to extend the cash runway to end of calendar 2028 and will support manufacturing and regulatory work for GTx-104, an IV nimodipine formulation for aSAH. However, NDA resubmission timing remains uncertain and dependent on manufacturing readiness, whether via a dual-source manufacturing strategy or remediation of the current contract manufacturer’s FDA compliance issues.

• · The private placement is priced at-the-market under Nasdaq rules and is expected to close August 6, 2026.
• · Craig-Hallum is acting as sole placement agent.
• · GTx-104 has Orphan Drug Designation from FDA, providing seven years of marketing exclusivity post-launch if conditions are met.
• · Nimodipine is currently administered orally via nasogastric tube; GTx-104 is designed for standard peripheral IV infusion, potentially eliminating nasogastric tube use and reducing dosing errors and drug-drug interactions.
• · The company reported significantly lower inter- and intra-subject pharmacokinetic variability for GTx-104 vs. oral capsules.

06-08-2026

ARKO Petroleum Corp. (APC) entered into a definitive Asset Purchase Agreement dated August 4, 2026, to acquire substantially all of the assets of a group of sellers (Midwest Texas Tea, USPP-Barrick, Oakland Fuels Holdings, Toledo Terminal Holdings, US Energy Transportation, USPP-Tri Lakes, More Cans Leasing, U.S. Energy Distribution, and Detroit Petroleum Properties entities) for an aggregate purchase price. The acquisition includes two terminal operations (Novi, Michigan and Toledo, Ohio), dealer-owned wholesale contracts, convenience stores in the greater Detroit metro area and northern Ohio, two offices, a truck yard, consignment contracts, and a fleet of 32 tractors, 26 trailers, and 11 other vehicles. The purchase price is not explicitly stated in the filing excerpt, but the agreement includes detailed representations, warranties, indemnification, and conditions precedent to closing.

• · The acquisition includes convenience stores branded under BP, Amoco, Shell, Sunoco, Mobil, Exxon, Citgo, and Marathon.
• · The sellers are a group of 15 Delaware limited liability companies.
• · The purchase price allocation, form of payment, and specific closing date are not disclosed in the excerpt.
• · The agreement includes a covenant not to compete and confidentiality provisions.
• · The parties have made HSR Act filings for the transaction.

06-08-2026

ARKO Corp., through its subsidiaries, has entered into a definitive Asset Purchase Agreement dated August 4, 2026, to acquire substantially all of the assets of a group of sellers operating a fuel distribution and retail business in the Great Lakes region. The acquisition includes two terminal operations, dealer and consignment contracts, convenience stores, offices, a truck yard, and a fleet of vehicles. The purchase price and specific financial terms are not disclosed in this excerpt.

• · The acquired business includes dealer-owned accounts (Wholesale Contracts) and long-term commission contracts (Consignment Contracts) serving wholesale and commercial/farm tank wagon customers in the Great Lakes region.
• · Convenience stores are primarily located in the greater Detroit metro area and northern Ohio.
• · The acquisition includes two terminal operations located in Novi, Michigan and Toledo, Ohio.
• · The purchase price allocation and form of payment are detailed in the agreement but not disclosed in this excerpt.
• · The parties have made the requisite HSR Act filing for the transaction.

06-08-2026

The filing reports an officer change at Omada Health, Inc., but no specific details about the departing or appointed officer, the reason for the change, or any financial metrics are disclosed. The filing references Items 2.02 (Results of Operations and Financial Condition), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), and 9.01 (Financial Statements and Exhibits), but the actual content of these items is not provided in the summary. Without specific data, the analysis is limited to the filing's structure and regulatory compliance.

• · Filing date: August 06, 2026
• · AccNo: 0001628280-26-054266
• · Size: 517 KB
• · Sector: not specified